Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,356.00+0.19%ETH$2,533.28+2.90%GOLD$4,390.30-0.39%OIL$100.30-2.13%
Smart Investors Daily
HR

NASDAQ · HRMY

Harmony Biosciences Holdings, Inc.

Healthcare · Biotechnology

$41.10

Up+$0.47 (+1.14%)

Updated Sep 11, 2026, 7:48 PM

SID Score

8.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.28B
P/E ratio
12.47
Dividend yield
0.00%
52-week range
$26.34 – $43.49
Volume
736.83K
Avg. volume
922.99K

Price performance

HRMY price history

1M range · 20 trading sessions · Daily adjusted prices

HRMY closed at $41.10 after 20 trading sessions, up 6.75% for the selected period.

Last close
$41.10
Period change
+6.75%
Period low
$38.07
Period high
$42.86
Daily close
View OHLC price history
HRMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$41.26$41.7208$40.93$41.10736.83K
Sep 9, 2026$42.01$42.405$41.23$41.621.13M
Sep 8, 2026$42.20$43.25$41.555$42.071.78M
Sep 4, 2026$41.50$42.34$41.3603$42.25662.55K
Sep 3, 2026$42.93$43.49$41.40$41.861.1M
Sep 2, 2026$41.31$43.02$41.25$42.861.17M
Sep 1, 2026$39.38$41.49$39.38$41.25894.9K
Aug 31, 2026$38.97$39.745$38.97$39.38560.16K
Aug 28, 2026$39.69$39.69$39.13$39.21590.22K
Aug 27, 2026$39.90$40.00$39.16$39.87499.04K
Aug 26, 2026$39.74$40.50$38.865$39.66745.2K
Aug 25, 2026$38.56$39.22$38.34$38.95375.52K
Aug 24, 2026$38.13$38.93$37.48$38.50486.07K
Aug 21, 2026$38.12$38.8403$38.015$38.15380.08K
Aug 20, 2026$39.61$40.02$37.93$38.07696.1K
Aug 19, 2026$39.05$39.99$38.51$39.93765.79K
Aug 18, 2026$38.19$39.11$38.15$38.83463.48K
Aug 17, 2026$38.12$38.53$37.75$38.14734.28K
Aug 14, 2026$38.22$38.455$37.87$38.12388.57K
Aug 13, 2026$39.89$40.15$38.43$38.50582.64K

Latest HRMY news

The latest Smart Investors Daily articles mentioning HRMY.

Stock researchCompany · Overview

HRMY research

Overview

Company profile and research snapshot.

Company profile

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$47.80
Implied upside
—
Analysts
17
HRMY recent ratings
DateFirmRatingTarget
Aug 26, 2026Wolfe ResearchOutperform—
Aug 5, 2026Truist SecuritiesHold—
Aug 4, 2026NeedhamBuy—
Jul 31, 2026MizuhoOutperform—
Jul 16, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece. The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are current

Yahoo · Aug 27, 2026

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesHarmony Biosciences

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By